Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rejuvesol is a sterile, non-pyrogenic solution composed of sodium pyruvate, inosine, adenine, dibasic sodium phosphate, and monobasic sodium phosphate in water for injection. It is designed exclusively for the extracorporeal rejuvenation of stored red blood cell (RBC) concentrates prior to transfusion. Rejuvesol restores depleted levels of adenosine triphosphate (ATP) and 2,3-diphosphoglycerate (2,3-DPG) in RBCs that have been stored for more than 14 days at 1–6°C. These molecules are critical for maintaining RBC membrane integrity and flexibility (ATP), as well as facilitating oxygen release from hemoglobin to tissues (2,3-DPG). By restoring these levels to those found in fresh blood, Rejuvesol improves the functional capacity of stored RBCs and enhances their effectiveness in oxygen delivery after transfusion. The product is not intended for direct administration to humans but must be mixed with red blood cells before transfusion[1][2][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rejuvesol.